Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royal Caribbean Cruises

Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.

These 3 Stocks Are Rallying While the Rest of the Market Plunges

Gilead Sciences, Inc. (NASDAQ:GILD ) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 1:00 PM ET Company Participants Andrew Dickinson - Executive Vice President & Chief Financial Officer William Grossman - Senior Vice President of Oncology Clinical Research Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Umer Raffat Excellent. Thank you guys for joining us.

Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript)

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

FOSTER CITY, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approval for Biktarvy in the European Union (EU) and applies to all 27 member states of the EU, as well as Norway, Iceland and Liechtenstein.

European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric Populations

BeiGene

Bio-Rad Laboratories

Catalent

DexCom

Edwards Lifesciences

Intuitive Surgical

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

Arcus Biosciences

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher. The post Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges appeared first on Investor's Business Daily.

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

FOSTER CITY, Calif. & HAYWARD, Calif.--( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab (doublet), and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist (triplet), versus zimberelimab alone, and represents the first randomized Phase 2 study of an Fc-silent anti-TIGIT/anti-PD-1 combination. The protocol-specified fourth interim analysis was conducted when the trial reached full enrollment, with a clinical data cutoff date of August 31, 2022. A total of 150 patients have been randomized across the three study arms.

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer

American Electric Power Company

Intel

Kraft Heinz

Walgreens

The Nasdaq has been absolutely obliterated this year, down a stunning 27%, which puts the tech-heavy index firmly in bear market territory.

Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Santa Claus Rally

General Mills

O'Reilly Automotive

Texas Roadhouse

A company capable of generating earnings well above its interest expense can withstand financial hardship. General Mills (GIS), Texas Roadhouse (TXRH), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are sound enough to meet financial obligations.

Pick These 4 Stocks With Exciting Interest Coverage Ratio

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly.

See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch

Pharmaceuticals producer and developer competitor activities often are hard to separate and the rapid development in biosciences tend to encourage the labeling of stocks as “healthcare”. The Covid-19 pandemic is just the most apparent precipitator of terminology generalization. Here our interest is more specific to the investing payoffs than to their scientific genre.

Gilead Sciences: Best Near-Term Biopharma Cap Gain Bet Say Market-Makers

“IBB” – the iShares Biotechnology ETF has already recovered about 30% over the past five months but Jefferies' Michael Yee is convinced it still has more room to the upside. Yee's bull case for the biotech stock Yee sees several catalysts that could potentially push these stocks further up in the coming months.

Is it too late to invest in the Biotech stocks?

Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.

Buy this Medical Sector Pioneer Stock

Halozyme Therapeutics

GILD vs. HALO: Which Stock Is the Better Value Option?

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Regeneron Pharmaceuticals

Both of these companies have potential catalysts on the way.

2 Top Biotech Stocks to Buy in November

Shares of Gilead Sciences have been have been on a tear recently.

Has This Hot Stock Run Out of Steam?

The company's growing oncology portfolio is driving increased revenues.

Why Shares of Gilead Sciences Rose 27.20% in October

Twitter

Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company.

Gilead, Kite in process of pausing Twitter advertising

AbbVie

Johnson & Johnson

There's no need for agonizing decision-making with these great dividend stocks.

3 No-Brainer Dividend Stocks to Buy in November

Gilead Sciences, Inc. (NASDAQ: GILD) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected third-quarter results last week, and the company's management updated financial guidance for the 2022 fiscal year.

News for Gilead Sciences Stock (GILD)